Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial

Publication date: Available online 27 February 2019Source: The Lancet HaematologyAuthor(s): Catriona Parker, Shekhar Krishnan, Lina Hamadeh, Julie A E Irving, Roland P Kuiper, Tamas Révész, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Anthony V Moorman, Vaskar SahaSummaryBackgroundThe ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.MethodsALLR3 was an open-label randomised clinical trial that recruited children aged 1–18 years with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. Eligible patients were recruited from centres in Australia, Ireland, the Netherlands, New Zealand, and the UK. Patients were randomly assigned from Jan 31, 2003, to Dec 31, 2007, and the trial closed to recruitment on Oct 31, 2013. Randomly assigned patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation; after randomisation stopped in Dec 31, 2007, all patients were allocated to receive mitoxantrone. After three blocks of therapy, patients with high minimal residual disease (≥10−4 cells) at the end of induction were allocated to undergo allogeneic stem-cell transplantation and those with low minimal residual disease (<10−4 cells) at the end of induction were allocated to receive chemotherapy. Minimal residual disease level was measured by re...
Source: The Lancet Haematology - Category: Hematology Source Type: research